试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-08
Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis
编号:NCT02907307登记状态:入组前撤回企业 / 申办者:Medinova AG
药物 / 成分:LactiSal vaginal gel 1%、LactiSal vaginal tablet 50mg、Clotrimazole vaginal tablet 100mg
登记的停止原因(原文):Development project stopped
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-08
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
编号:NCT03167957登记状态:入组前撤回企业 / 申办者:Matinas BioPharma Nanotechnologies, Inc.
药物 / 成分:Oral Encochleated Amphotericin B (CAMB)、Oral Encochleated Amphotericin B (CAMB)
登记的停止原因(原文):No longer target indication
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-08
Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia
编号:NCT03187691登记状态:入组前撤回企业 / 申办者:Matinas BioPharma Nanotechnologies, Inc.
药物 / 成分:Oral Encochleated Amphotericin B (CAMB)
登记的停止原因(原文):Protocol redundancy
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-08
Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection
编号:NCT03196921登记状态:入组前撤回企业 / 申办者:Matinas BioPharma Nanotechnologies, Inc.
药物 / 成分:Encochleated Amphotericin B
登记的停止原因(原文):Protocol redundancy
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-08
Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia
编号:NCT03705858登记状态:入组前撤回企业 / 申办者:Joseph Jurcic
药物 / 成分:Ac-Lintuzumab
登记的停止原因(原文):Due to difficulty in finalizing the contract
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-07
Epidural Dexamethasone for Labor Analgesia: the Effects on Ropivacaine Consumption and Labour Outcome
编号:NCT02857465登记状态:入组前撤回企业 / 申办者:Centre Hospitalier Universitaire de la Réunion
药物 / 成分:Dexamethasone、Placebo、Ropivacaine、Sufentanil
登记的停止原因(原文):French Agency for the Safety of Health Products refusal
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-07
Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy
编号:NCT03196765登记状态:入组前撤回企业 / 申办者:NeuroVia, Inc.
药物 / 成分:Sobetirome (NV1205)
登记的停止原因(原文):No funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-07
The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma
编号:NCT03255330登记状态:入组前撤回企业 / 申办者:Masaryk University
药物 / 成分:Gabapentin、Metamizol、Tramadol
登记的停止原因(原文):no participant enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-07
Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome
编号:NCT03695822登记状态:入组前撤回企业 / 申办者:Far Eastern Memorial Hospital
药物 / 成分:Mirabegron 25mg
登记的停止原因(原文):I did not pass the 2018 Ministry of Science and Technology research project subsidy, so I applied for the project to close the case.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-06
Vitamin C for Severe Thermal Injuries
编号:NCT01587261登记状态:入组前撤回企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:Vitamin C、Placebo
登记的停止原因(原文):This potential study was held up at the level of the FDA as they wouldn't approve and IND for the dose of vitamin C we wanted to use.
查看官方原始记录 ↗